Clinical Trials in Illinois

Browse 248 Illinois Medical Studies Across 1374 Cities

118 Phase 3 Trial · 16536 Illinois Clinics

Reviewed by Michael Gill, B. Sc.
Photo of Lexington 1
Phase-Based Progress Estimates

Dronedaronefor Atrial Fibrillation

Lexington, KY
All Sexes
While there are several completed clinical trials that address treatment strategy in patients with symptomatic and recurrent AF, there are no randomized clinical trials that address treatment for first-detected AF. In usual care, these patients are started on an atrioventricular nodal blocking agent (beta-blocker or non-dihydropyridine calcium channel blocker) along with stroke prevention therapy. The investigators hypothesize that earlier administration of a well-tolerated antiarrhythmic drug proven to reduce hospitalization may result in improved cardiovascular outcomes and quality of life in patients first-detected AF. The purpose of this study is to determine if treatment with dronedarone on top of usual care is superior to usual care alone for the prevention of cardiovascular hospitalization or death from any cause in patients hospitalized with first-detected AF. All patients will be treated with guideline-recommended stroke prevention therapy according to the CHA2DS2-VASc score. The treatment follow-up period will be 12 months. There will be two follow-up visits. Consistent with the pragmatic nature of the trial, the first follow-up will occur between 3 -9 months and the 2nd will occur at 12 months (with a window of +/- 30 days). Approximately 3000 patients will be enrolled and randomly assigned (1:1) to study intervention. The study intervention will be dronedarone 400 mg twice daily in addition to usual care versus usual care alone.
Phase 4
Photo of illinois 1
Phase-Based Progress Estimates

Radiation Therapyfor Adenocarcinoma

DeKalb, IL
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness. The Decipher risk score evaluates a prostate cancer tumor for its potential for spreading. In patients with low risk scores, this trial compares radiation therapy alone to the usual treatment of radiation therapy and hormone therapy (androgen deprivation therapy). Radiation therapy uses high energy x-rays or particles to kill tumor cells and shrink tumors. Androgen deprivation therapy blocks the production or interferes with the action of male sex hormones such as testosterone, which plays a role in prostate cancer development. Giving radiation treatment alone may be the same as the usual approach in controlling the cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy. In patients with higher Decipher gene risk, this trial compares the addition of darolutamide to usual treatment radiation therapy and hormone therapy, to usual treatment. Darolutamide blocks the actions of the androgens (e.g. testosterone) in the tumor cells and in the body. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading.
Phase 3
25 Illinois Clinical Trials Near Me
Lemont, IL
San Antonio, TX
Indianapolis, IN
Boston, MA
More Trial Locations
An interactive map to display trial locations for University Retina - Lemont, Retinal Consultants of San Antonio, Midwest Eye Institute - North, Ophthalmic Consultants of Boston, and 1183 more locations.
Most Popular References for Illinois Clinical Trials
Top Cities for Illinois Clinical Trials
Active Illinois Clinical Trials
Top Active Site for Illinois Clinical Trials
Trial List
Saint Louis, Missouri
Washington University School of Medicine
New York, New York
Memorial Sloan Kettering Cancer Center
Most Recent Illinois Clinical Trials
Pediatric Illinois Clinical Trials
Clinical Trial
Began Recruiting Date
Senior Friendly Illinois Clinical Trials

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 3rd, 2021

Last Reviewed: August 2nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.